Literature DB >> 11517236

Neuroprotection by Delta9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity.

M van der Stelt1, W B Veldhuis, P R Bär, G A Veldink, J F Vliegenthart, K Nicolay.   

Abstract

Excitotoxicity is a paradigm used to explain the biochemical events in both acute neuronal damage and in slowly progressive, neurodegenerative diseases. Here, we show in a longitudinal magnetic resonance imaging study that Delta(9)-tetrahydrocannabinol (Delta(9)-THC), the main active compound in marijuana, reduces neuronal injury in neonatal rats injected intracerebrally with the Na(+)/K(+)-ATPase inhibitor ouabain to elicit excitotoxicity. In the acute phase Delta(9)-THC reduced the volume of cytotoxic edema by 22%. After 7 d, 36% less neuronal damage was observed in treated rats compared with control animals. Coadministration of the CB(1) cannabinoid receptor antagonist SR141716 prevented the neuroprotective actions of Delta(9)-THC, indicating that Delta(9)-THC afforded protection to neurons via the CB(1) receptor. In Delta(9)-THC-treated rats the volume of astrogliotic tissue was 36% smaller. The CB(1) receptor antagonist did not block this effect. These results provide evidence that the cannabinoid system can serve to protect the brain against neurodegeneration.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11517236      PMCID: PMC6763099     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  45 in total

Review 1.  Pathobiology of ischaemic stroke: an integrated view.

Authors:  U Dirnagl; C Iadecola; M A Moskowitz
Journal:  Trends Neurosci       Date:  1999-09       Impact factor: 13.837

2.  The neurotoxicity of ouabain, a sodium-potassium ATPase inhibitor, in the rat hippocampus.

Authors:  G J Lees; A Lehmann; M Sandberg; A Hamberger
Journal:  Neurosci Lett       Date:  1990-12-11       Impact factor: 3.046

Review 3.  Formation of N-acyl-phosphatidylethanolamines and N-acetylethanolamines: proposed role in neurotoxicity.

Authors:  H S Hansen; L Lauritzen; B Moesgaard; A M Strand; H H Hansen
Journal:  Biochem Pharmacol       Date:  1998-03-15       Impact factor: 5.858

Review 4.  Pharmacology of cannabinoid CB1 and CB2 receptors.

Authors:  R G Pertwee
Journal:  Pharmacol Ther       Date:  1997       Impact factor: 12.310

5.  Neurotoxicity of glutamate in chick telencephalon neurons: reduction of toxicity by preincubation with carbachol, but not by the endogenous fatty acid amides anandamide and palmitoylethanolamide.

Authors:  M Andersson; S O Jacobsson; K O Jonsson; G Tiger; C J Fowler
Journal:  Arch Toxicol       Date:  2000-05       Impact factor: 5.153

6.  Cyclo-oxygenase-2 mediates P2Y receptor-induced reactive astrogliosis.

Authors:  R Brambilla; G Burnstock; A Bonazzi; S Ceruti; F Cattabeni; M P Abbracchio
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

Review 7.  Cardiovascular effects of endocannabinoids--the plot thickens.

Authors:  G Kunos; Z Járai; K Varga; J Liu; L Wang; J A Wagner
Journal:  Prostaglandins Other Lipid Mediat       Date:  2000-04       Impact factor: 3.072

8.  Glutamate release through volume-activated channels during spreading depression.

Authors:  T A Basarsky; D Feighan; B A MacVicar
Journal:  J Neurosci       Date:  1999-08-01       Impact factor: 6.167

9.  Early evolution and recovery from excitotoxic injury in the neonatal rat brain: a study combining magnetic resonance imaging, electrical impedance, and histology.

Authors:  M van Lookeren Campagne; J B Verheul; K Nicolay; R Balázs
Journal:  J Cereb Blood Flow Metab       Date:  1994-11       Impact factor: 6.200

10.  Manipulation of membrane potential modulates malonate-induced striatal excitotoxicity in vivo.

Authors:  J G Greene; J T Greenamyre
Journal:  J Neurochem       Date:  1996-02       Impact factor: 5.372

View more
  41 in total

1.  Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation.

Authors:  Belén G Ramírez; Cristina Blázquez; Teresa Gómez del Pulgar; Manuel Guzmán; María L de Ceballos
Journal:  J Neurosci       Date:  2005-02-23       Impact factor: 6.167

Review 2.  Endocannabinoids in the dentate gyrus.

Authors:  Charles J Frazier
Journal:  Prog Brain Res       Date:  2007       Impact factor: 2.453

3.  Cannabinoid Receptor Type 1 Agonist ACEA Protects Neurons from Death and Attenuates Endoplasmic Reticulum Stress-Related Apoptotic Pathway Signaling.

Authors:  Talita A Vrechi; Fernanda Crunfli; Andressa P Costa; Andréa S Torrão
Journal:  Neurotox Res       Date:  2017-11-13       Impact factor: 3.911

Review 4.  Biosynthesis of endocannabinoids and their modes of action in neurodegenerative diseases.

Authors:  Mario van der Stelt; Henrik H Hansen; Wouter B Veldhuis; Peter R Bär; Klaas Nicolay; Gerrit A Veldink; Johannes F G Vliegenthart; Harald S Hansen
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

5.  Brain levels of N-acylethanolamine phospholipids in mice during pentylenetetrazol-induced seizure.

Authors:  Birthe Moesgaard; Henrik H Hansen; Suzanne L Hansen; Steen Honore Hansen; Gitte Petersen; Harald S Hansen
Journal:  Lipids       Date:  2003-04       Impact factor: 1.880

Review 6.  Cannabinoids and Epilepsy.

Authors:  Evan C Rosenberg; Richard W Tsien; Benjamin J Whalley; Orrin Devinsky
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

7.  The CB1 antagonist, SR141716A, is protective in permanent photothrombotic cerebral ischemia.

Authors:  Zachary Wilmer Reichenbach; Hongbo Li; Sara Jane Ward; Ronald F Tuma
Journal:  Neurosci Lett       Date:  2016-07-21       Impact factor: 3.046

Review 8.  Role of cannabinoids and endocannabinoids in cerebral ischemia.

Authors:  Cecilia J Hillard
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

9.  Genomic and proteomic analysis of the effects of cannabinoids on normal human astrocytes.

Authors:  B Bindukumar; S D Mahajan; J L Reynolds; Z Hu; D E Sykes; R Aalinkeel; S A Schwartz
Journal:  Brain Res       Date:  2007-11-01       Impact factor: 3.252

Review 10.  Cannabinoids in multiple sclerosis: do they have a therapeutic role?

Authors:  Joep Killestein; Bernard M J Uitdehaag; Chris H Polman
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.